Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAPAE01 + amoxicillin + clarithromycin
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a **combination drug** comprised of RAPAE01, amoxicillin, and clarithromycin. Amoxicillin and clarithromycin are both antibiotics frequently used together in the treatment of **Helicobacter pylori infection**, often as part of a triple or quadruple therapy. Their action involves cell wall synthesis inhibition (amoxicillin) and protein synthesis inhibition (clarithromycin), respectively. The precise identity and mechanism of RAPAE01 are not established in available references; therefore, no specific mechanism or indication beyond the context of combination antibiotic therapy for H. pylori can be assigned.
02
Targets
Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on RAPAE01 + amoxicillin + clarithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAPAE01 + amoxicillin + clarithromycin.